A nurse is caring for a client who has a new diagnosis of chronic kidney disease. Which of the following statements should the nurse identify as an Indication of anticipatory grieving?

A. Prothrombin time (PT): Warfarin works by inhibiting vitamin K–dependent clotting factors, which prolongs the PT. Monitoring PT, often reported as the INR (international normalized ratio), is the standard for assessing the therapeutic effect and dose adjustment of warfarin therapy.

B. Hemoglobin (Hb): Hemoglobin levels help detect anemia or blood loss, which may indicate bleeding complications. However, Hb does not measure the effectiveness of anticoagulation and is therefore not the primary value to monitor for therapeutic effect.

C. Activated partial thromboplastin time (aPTT): aPTT is used to monitor heparin therapy, not warfarin. Although both are anticoagulants, they affect different clotting pathways, and aPTT does not reliably indicate warfarin’s therapeutic effect.

D. Bleeding time: Bleeding time evaluates platelet function and the ability to form clots at the capillary level. Warfarin primarily affects the coagulation cascade rather than platelet activity, so bleeding time is not a useful measure of its therapeutic effect.

A. Flatulence: While some antacids may cause mild bloating or gas, flatulence is not a primary adverse effect of aluminum hydroxide and does not usually require monitoring or reporting.

B. Constipation: Aluminum hydroxide commonly causes constipation because it slows gastrointestinal motility. Clients should be instructed to report persistent constipation and may need dietary adjustments or stool softeners to manage this side effect.

C. Palpitations: Palpitations are not associated with aluminum hydroxide use. Cardiovascular monitoring is generally unnecessary unless other conditions or medications are present.

D. Headache: Headaches are not a typical adverse effect of aluminum hydroxide. Monitoring for neurological symptoms is not required with standard antacid therapy.